‘New Gold Standard’ for Previously Untreated CLL
SAN DIEGO — A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the randomized FLAIR trial indicated. At 3 years, progression-free survival (PFS) rates reached 97% for patients randomized to venetoclax (Venclexta) plus ibrutinib (Imbruvica), as compared with 77% […]
Adding Regorafenib in First-Line ‘Promising’ in Gastric Cancer
Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy regimen for HER2-negative metastatic esophagogastric cancer demonstrated “promising” activity in a single-arm phase II study, according to researchers. Among 35 evaluable patients treated with the tyrosine kinase inhibitor (TKI) plus nivolumab (Opdivo) and FOLFOX chemotherapy, 25 (71%, 95% CI 54-85) remained progression free at 6 months, thus […]
Early Promise for Pembrolizumab Plus Chemo in RR Hodgkin’s Lymphoma
A chemoimmunotherapy regimen led to a 100% response rate as second-line therapy for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), a small phase II trial showed. All 38 evaluable patients achieved objective responses with the combination of pembrolizumab (Keytruda), gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD), including complete responses in 36 of 38 cases. All but two […]